{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:20:33Z","timestamp":1793740833968,"version":"4.6.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Bronchopulmonary dysplasia (BPD) is a major complication in prematurely born infants. Pulmonary hypertension (PH) associated with BPD (BPD-PH) is characterized by alveolar diffusion impairment, abnormal vascular remodeling, and rarefication of pulmonary vessels (vascular growth arrest), which lead to increased pulmonary vascular resistance and right heart failure. About 25% of infants with moderate to severe BPD develop BPD-PH that is associated with high morbidity and mortality. The recent evolution of broader PH-targeted pharmacotherapy in adults has opened up new treatment options for infants with BPD-PH. Sildenafil became the mainstay of contemporary BPD-PH therapy. Additional medications, such as endothelin receptor antagonists and prostacyclin analogs\/mimetics, are increasingly being investigated in infants with PH. However, pediatric data from prospective or randomized controlled trials are still sparse. We discuss comprehensive diagnostic and therapeutic strategies for BPD-PH and briefly review the relevant differential diagnoses of parenchymal and interstitial developmental lung diseases. In addition, we provide a practical framework for the management of children with BPD-PH, incorporating the modified definition and classification of pediatric PH from the 2018 World Symposium on Pulmonary Hypertension, and the 2019 EPPVDN consensus recommendations on established and newly developed therapeutic strategies. Finally, current gaps of knowledge and future research directions are discussed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Impact<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>PH in BPD substantially increases mortality. Treatment of BPD-PH should be conducted by an interdisciplinary team and follow our new treatment algorithm while still kept tailored to the individual patient.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>We discuss recent developments in BPD-PH, make recommendations on diagnosis, monitoring and treatment of PH in BPD, and address current gaps of knowledge and potential research directions.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>We provide a practical framework, including a new treatment algorithm, for the management of children with BPD-PH, incorporating the modified definition and classification of pediatric PH (2018 WSPH) and the 2019 EPPVDN consensus recommendations on established and newly developed therapeutic strategies for BPD-PH.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41390-020-0993-4","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T03:02:49Z","timestamp":1591758169000},"page":"446-455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":227,"title":["Pulmonary hypertension in bronchopulmonary dysplasia"],"prefix":"10.1038","volume":"89","author":[{"given":"Georg","family":"Hansmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Sallmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Roehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Kourembanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Koestenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the European Pediatric Pulmonary Vascular Disease Network (EPPVDN)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"993_CR1","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/jama.2015.10244","volume":"314","author":"BJ Stoll","year":"2015","unstructured":"Stoll, B. J. et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993\u20132012. JAMA 314, 1039\u20131051 (2015).","journal-title":"JAMA"},{"key":"993_CR2","doi-asserted-by":"crossref","first-page":"L832","DOI":"10.1152\/ajplung.00369.2019","volume":"317","author":"E Lignelli","year":"2019","unstructured":"Lignelli, E., Palumbo, F., Myti, D. & Morty, R. E. Recent advances in our understanding of the mechanisms of lung alveolarization and bronchopulmonary dysplasia. Am. J. Physiol. Lung Cell. Mol. Physiol. 317, L832\u2013L887 (2019).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"993_CR3","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/jp.2016.255","volume":"37","author":"CG Weismann","year":"2017","unstructured":"Weismann, C. G. et al. Pulmonary hypertension in preterm infants: results of a prospective screening program. J. Perinatol. 37, 572\u2013577 (2017).","journal-title":"J. Perinatol."},{"key":"993_CR4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1164\/rccm.201409-1594OC","volume":"191","author":"PM Mourani","year":"2015","unstructured":"Mourani, P. M. et al. Early pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 191, 87\u201395 (2015).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"993_CR5","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1542\/peds.2007-0971","volume":"120","author":"E Khemani","year":"2007","unstructured":"Khemani, E. et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 120, 1260\u20131269 (2007).","journal-title":"Pediatrics"},{"key":"993_CR6","doi-asserted-by":"crossref","unstructured":"Altit, G., Bhombal. S., Feinstein, J., Hopper, R. K. & Tacy, T. A. Diminished right ventricular function at diagnosis of pulmonary hypertension is associated with mortality in bronchopulmonary dysplasia. Pulm. Circ. 9, 2045894019878598 (2019).","DOI":"10.1177\/2045894019878598"},{"key":"993_CR7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jpeds.2019.04.046","volume":"211","author":"MS Ong","year":"2019","unstructured":"Ong, M. S. et al. Racial and ethnic differences in pediatric pulmonary hypertension: an analysis of the Pediatric Pulmonary Hypertension Network Registry. J. Pediatr. 211, 63\u201371.e6 (2019).","journal-title":"J. Pediatr."},{"key":"993_CR8","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/jp.2016.108","volume":"36","author":"H Nakanishi","year":"2016","unstructured":"Nakanishi, H., Uchiyama, A. & Kusuda, S. Impact of pulmonary hypertension on neurodevelopmental outcome in preterm infants with bronchopulmonary dysplasia: a cohort study. J. Perinatol. 36, 890\u2013896 (2016).","journal-title":"J. Perinatol."},{"key":"993_CR9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12887-019-1400-3","volume":"19","author":"EK Choi","year":"2019","unstructured":"Choi, E. K., Shin, S. H., Kim, E. K. & Kim, H. S. Developmental outcomes of preterm infants with bronchopulmonary dysplasia-associated pulmonary hypertension at 18-24\u2009months of corrected age. BMC Pediatr. 19, 26 (2019).","journal-title":"BMC Pediatr."},{"key":"993_CR10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jpeds.2018.07.035","volume":"203","author":"JM Lagatta","year":"2018","unstructured":"Lagatta, J. M. et al. The impact of pulmonary hypertension in preterm infants with severe bronchopulmonary dysplasia through 1 year. J. Pediatr. 203, 218\u2013224.e3 (2018).","journal-title":"J. Pediatr."},{"key":"993_CR11","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1164\/rccm.201710-2016OC","volume":"198","author":"KN Goss","year":"2018","unstructured":"Goss, K. N. et al. Early pulmonary vascular disease in young adults born preterm. Am. J. Respir. Crit. Care Med. 198, 1549\u20131558 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"993_CR12","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.healun.2019.06.022","volume":"38","author":"G Hansmann","year":"2019","unstructured":"Hansmann, G. et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J. Heart Lung Transplant. 38, 879\u2013901 (2019).","journal-title":"J. Heart Lung Transplant."},{"key":"993_CR13","doi-asserted-by":"crossref","first-page":"1801916","DOI":"10.1183\/13993003.01916-2018","volume":"53","author":"EB Rosenzweig","year":"2019","unstructured":"Rosenzweig, E. B. et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur. Respir. J. 53, 1801916 (2019).","journal-title":"Eur. Respir. J."},{"key":"993_CR14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Galie","year":"2016","unstructured":"Galie, N. et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J. 37, 67\u2013119 (2016).","journal-title":"Eur. Heart J."},{"key":"993_CR15","doi-asserted-by":"crossref","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","volume":"53","author":"G Simonneau","year":"2019","unstructured":"Simonneau, G. et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur. Respir. J. 53, 1801913 (2019).","journal-title":"Eur. Respir. J."},{"key":"993_CR16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1164\/rccm.201706-1215OC","volume":"197","author":"P Douschan","year":"2018","unstructured":"Douschan, P. et al. Mild elevation of pulmonary arterial pressure as a predictor of mortality. Am. J. Respir. Crit. Care Med. 197, 509\u2013516 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"993_CR17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.4103\/2045-8932.83456","volume":"1","author":"MJ Cerro","year":"2011","unstructured":"Cerro, M. J. et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: report from the PVRI Pediatric Taskforce, Panama 2011. Pulm. Circ. 1, 286\u2013298 (2011).","journal-title":"Pulm. Circ."},{"key":"993_CR18","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1017\/S104795111900235X","volume":"29","author":"H Sallmon","year":"2019","unstructured":"Sallmon, H. et al. Recommendations from the Association for European Paediatric and Congenital Cardiology for training in pulmonary hypertension. Cardiol. Young. 29, 1323\u20131327 (2019).","journal-title":"Cardiol. Young."},{"key":"993_CR19","doi-asserted-by":"crossref","first-page":"1900788","DOI":"10.1183\/13993003.00788-2019","volume":"55","author":"L Duijts","year":"2020","unstructured":"Duijts, L. et al. European Respiratory Society guideline on long term management of children with bronchopulmonary dysplasia. Eur. Respir. J. 55, 1900788 (2020).","journal-title":"Eur. Respir. J."},{"key":"993_CR20","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.cmet.2017.03.011","volume":"25","author":"L Calvier","year":"2017","unstructured":"Calvier, L. et al. PPAR\u03b3 links BMP2 and TGF\u03b21 pathways in vascular smooth muscle cells, regulating cell proliferation and glucose metabolism. Cell. Metab. 25, 1118\u20131134.e7 (2017).","journal-title":"Cell. Metab."},{"key":"993_CR21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41572-019-0127-7","volume":"5","author":"B Th\u00e9baud","year":"2019","unstructured":"Th\u00e9baud, B. et al. Bronchopulmonary dysplasia. Nat. Rev. Dis. Prim. 5, 78 (2019).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"993_CR22","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1164\/ajrccm.163.7.2011060","volume":"163","author":"AH Jobe","year":"2001","unstructured":"Jobe, A. H. & Bancalari, E. Bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 163, 1723\u20131729 (2001).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"993_CR23","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1164\/rccm.201812-2348OC","volume":"200","author":"EA Jensen","year":"2019","unstructured":"Jensen, E. A. et al. The diagnosis of bronchopulmonary dysplasia in very preterm infants. An evidence-based approach. Am. J. Respir. Crit. Care Med. 200, 751\u2013759 (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"993_CR24","doi-asserted-by":"crossref","first-page":"e000878","DOI":"10.1161\/CIRCIMAGING.113.000878","volume":"8","author":"MJ Ploegstra","year":"2015","unstructured":"Ploegstra, M. J. et al. Echocardiography in pediatric pulmonary arterial hypertension: early study on assessing disease severity and predicting outcome. Circ. Cardiovasc. Imaging 8, e000878 (2015).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"993_CR25","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00246-015-1332-0","volume":"37","author":"M Koestenberger","year":"2016","unstructured":"Koestenberger, M. et al. Echocardiographic reference values for right atrial size in children with and without atrial septal defects or pulmonary hypertension. Pediatr. Cardiol. 37, 686\u2013695 (2016).","journal-title":"Pediatr. Cardiol."},{"key":"993_CR26","doi-asserted-by":"crossref","first-page":"e004612","DOI":"10.1161\/CIRCIMAGING.116.004612","volume":"9","author":"DA Burkett","year":"2016","unstructured":"Burkett, D. A. et al. Impact of pulmonary hemodynamics and ventricular interdependence on left ventricular diastolic function in children with pulmonary hypertension. Circ. Cardiovasc. Imaging 9, e004612 (2016).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"993_CR27","doi-asserted-by":"crossref","first-page":"e005527","DOI":"10.1161\/CIRCIMAGING.116.005527","volume":"9","author":"G Hansmann","year":"2016","unstructured":"Hansmann, G. Left ventricular diastolic dysfunction in pediatric pulmonary hypertension. Circ. Cardiovasc. Imaging 9, e005527 (2016).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"993_CR28","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.echo.2019.10.012","volume":"33","author":"H Nawaytou","year":"2020","unstructured":"Nawaytou, H. et al. Clinical utility of echocardiography in former preterm infants with bronchopulmonary dysplasia. J. Am. Soc. Echocardiogr. 33, 378\u2013388.e1 (2020).","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"993_CR29","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/thoraxjnl-2012-203020","volume":"68","author":"S Rajaram","year":"2013","unstructured":"Rajaram, S. et al. 3D contrast-enhanced lung perfusion MRI is an effective screening tool for chronic thromboembolic pulmonary hypertension: results from the ASPIRE Registry. Thorax 68, 677\u2013678 (2013).","journal-title":"Thorax"},{"key":"993_CR30","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1148\/radiol.2015150765","volume":"279","author":"C Schoenfeld","year":"2016","unstructured":"Schoenfeld, C. et al. MR imaging-derived regional pulmonary parenchymal perfusion and cardiac function for monitoring patients with chronic thromboembolic pulmonary hypertension before and after pulmonary endarterectomy. Radiology 279, 925\u2013934 (2016).","journal-title":"Radiology"},{"key":"993_CR31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1164\/rccm.201904-0826OC","volume":"201","author":"PJ Critser","year":"2020","unstructured":"Critser, P. J. et al. Cardiac magnetic resonance imaging evaluation of neonatal bronchopulmonary dysplasia-associated pulmonary hypertension. Am. J. Respir. Crit. Care Med. 201, 73\u201382 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"993_CR32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12968-015-0113-5","volume":"17","author":"S Kato","year":"2015","unstructured":"Kato, S. et al. Prognostic value of cardiovascular magnetic resonance derived right ventricular function in patients with interstitial lung disease. J. Cardiovasc. Magn. Reson. 17, 10 (2015).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"993_CR33","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ppul.24297","volume":"54","author":"MA Steurer","year":"2019","unstructured":"Steurer, M. A. et al. Mortality in infants with bronchopulmonary dysplasia: data from cardiac catheterization. Pediatr. Pulmonol. 54, 804\u2013813 (2019).","journal-title":"Pediatr. Pulmonol."},{"key":"993_CR34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S2213-2600(16)00069-2","volume":"4","author":"MJ Ploegstra","year":"2016","unstructured":"Ploegstra, M. J. et al. Growth in children with pulmonary arterial hypertension: a longitudinal retrospective multiregistry study. Lancet Respir. Med. 4, 281\u2013290 (2016).","journal-title":"Lancet Respir. Med."},{"key":"993_CR35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jpeds.2018.12.004","volume":"208","author":"BS Frank","year":"2019","unstructured":"Frank, B. S. et al. Acute vasoreactivity testing during cardiac catheterization of neonates with bronchopulmonary dysplasia-associated pulmonary hypertension. J. Pediatr. 208, 127\u2013133 (2019).","journal-title":"J. Pediatr."},{"key":"993_CR36","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijcard.2015.01.038","volume":"184","author":"MJ Ploegstra","year":"2015","unstructured":"Ploegstra, M. J., Zijlstra, W. M., Douwes, J. M., Hillege, H. L. & Berger, R. M. Prognostic factors in pediatric pulmonary arterial hypertension: a systematic review and meta-analysis. Int. J. Cardiol. 184, 198\u2013207 (2015).","journal-title":"Int. J. Cardiol."},{"key":"993_CR37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00246-008-9258-4","volume":"30","author":"A Nir","year":"2009","unstructured":"Nir, A. et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr. Cardiol. 30, 3\u20138 (2009).","journal-title":"Pediatr. Cardiol."},{"key":"993_CR38","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/ppul.24053","volume":"53","author":"S Rodr\u00edguez-Blanco","year":"2018","unstructured":"Rodr\u00edguez-Blanco, S. et al. N-terminal-probrain natriuretic peptide as a biomarker of moderate to severe bronchopulmonary dysplasia in preterm infants: a prospective observational study. Pediatr. Pulmonol. 53, 1073\u20131081 (2018).","journal-title":"Pediatr. Pulmonol."},{"key":"993_CR39","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fped.2019.00166","volume":"7","author":"L Zhou","year":"2019","unstructured":"Zhou, L. et al. N-terminal Pro-B-type natriuretic peptide as a biomarker of bronchopulmonary dysplasia or death in preterm infants: a retrospective cohort analysis. Front. Pediatr. 7, 166 (2019).","journal-title":"Front. Pediatr."},{"key":"993_CR40","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000442043","volume":"109","author":"AM Montgomery","year":"2016","unstructured":"Montgomery, A. M. et al. Biochemical screening for pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Neonatology 109, 190\u2013194 (2016).","journal-title":"Neonatology"},{"key":"993_CR41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jpeds.2018.09.067","volume":"205","author":"JL Cohen","year":"2019","unstructured":"Cohen, J. L. et al. Sildenafil use in children with pulmonary hypertension. J. Pediatr. 205, 29\u201334.e1 (2019).","journal-title":"J. Pediatr."},{"key":"993_CR42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ppul.23508","volume":"52","author":"G Kadmon","year":"2017","unstructured":"Kadmon, G. et al. Pulmonary hypertension specific treatment in infants with bronchopulmonary dysplasia. Pediatr. Pulmonol. 52, 77\u201383 (2017).","journal-title":"Pediatr. Pulmonol."},{"key":"993_CR43","doi-asserted-by":"publisher","unstructured":"Hansmann, G., Meinel, K., Bukova, M., Chouvarine, P., W\u00e5hlander, H. & Koestenberger, M.; European Pediatric Pulmonary Vascular Disease Network (EPPVDN). Selexipag for the Treatment of Children With Pulmonary Arterial Hypertension: First Multicenter Experience in Drug Safety and Efficacy. J. Heart Lung Transplant. (2020). https:\/\/doi.org\/10.1016\/j.healun.2020.03.029. [Online ahead of print].","DOI":"10.1016\/j.healun.2020.03.029"},{"key":"993_CR44","doi-asserted-by":"publisher","DOI":"10.21037\/cdt.2020.04.01","author":"S Schweintzger","year":"2020","unstructured":"Schweintzger, S. et al. Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension. Cardiovasc. Diagn. Ther. https:\/\/doi.org\/10.21037\/cdt.2020.04.01 (2020).","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"993_CR45","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jpeds.2008.09.021","volume":"154","author":"PM Mourani","year":"2009","unstructured":"Mourani, P. M., Sontag, M. K., Ivy, D. D. & Abman, S. H. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J. Pediatr. 154, 379\u2013384 (2009).","journal-title":"J. Pediatr."},{"key":"993_CR46","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1053\/j.semperi.2015.12.004","volume":"40","author":"S Lakshminrusimha","year":"2016","unstructured":"Lakshminrusimha, S., Mathew, B. & Leach, C. L. Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide. Semin. Perinatol. 40, 160\u2013173 (2016).","journal-title":"Semin. Perinatol."},{"key":"993_CR47","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"Ghofrani, H. A. et al. Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 369, 330\u2013340 (2013).","journal-title":"N. Engl. J. Med."},{"key":"993_CR48","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1161\/CIR.0000000000000329","volume":"132","author":"SH Abman","year":"2015","unstructured":"Abman, S. H. et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation 132, 2037\u20132099 (2015).","journal-title":"Circulation"},{"key":"993_CR49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jpeds.2017.05.029","volume":"188","author":"U Krishnan","year":"2017","unstructured":"Krishnan, U. et al. Evaluation and management of pulmonary hypertension in children with bronchopulmonary dysplasia. J. Pediatr. 188, 24\u201334.e1 (2017).","journal-title":"J. Pediatr."},{"key":"993_CR50","doi-asserted-by":"publisher","unstructured":"Tzoumas, N., Farrah, T. E., Dhaun, N. & Webb, D. J. Established and emerging therapeutic uses of phosphodiesterase type 5 inhibitors in cardiovascular disease. Br. J. Pharmacol. https:\/\/doi.org\/10.1111\/bph.14920 (2019).","DOI":"10.1111\/bph.14920"},{"key":"993_CR51","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1161\/CIRCULATIONAHA.113.005698","volume":"129","author":"RJ Barst","year":"2014","unstructured":"Barst, R. J. et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation 129, 1914\u20131923 (2014).","journal-title":"Circulation"},{"key":"993_CR52","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2005.01.066","volume":"46","author":"EB Rosenzweig","year":"2005","unstructured":"Rosenzweig, E. B. et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J. Am. Coll. Cardiol. 46, 697\u2013704 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"993_CR53","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0009-9236(03)00005-5","volume":"73","author":"RJ Barst","year":"2003","unstructured":"Barst, R. J. et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin. Pharmacol. Ther. 73, 372\u2013382 (2003).","journal-title":"Clin. Pharmacol. Ther."},{"key":"993_CR54","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1365-2125.2009.03532.x","volume":"68","author":"M Beghetti","year":"2009","unstructured":"Beghetti, M. et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br. J. Clin. Pharmacol. 68, 948\u2013955 (2009).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"993_CR55","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijcard.2015.08.080","volume":"202","author":"RM Berger","year":"2016","unstructured":"Berger, R. M. et al. FUTURE-2: results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. Int. J. Cardiol. 202, 52\u201358 (2016).","journal-title":"Int. J. Cardiol."},{"key":"993_CR56","doi-asserted-by":"crossref","unstructured":"Koestenberger, M. et al. Ventricular\u2013ventricular interaction variables correlate with surrogate variables of clinical outcome in children with pulmonary hypertension. Pulm. Circ. 9, 2045894019854074 (2019).","DOI":"10.1177\/2045894019854074"},{"key":"993_CR57","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2007.09.031","volume":"51","author":"DD Ivy","year":"2008","unstructured":"Ivy, D. D. et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J. Am. Coll. Cardiol. 51, 161\u2013169 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"993_CR58","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ppul.21619","volume":"47","author":"M Piastra","year":"2012","unstructured":"Piastra, M. et al. Nebulized iloprost and noninvasive respiratory support for impending hypoxaemic respiratory failure in formerly preterm infants: a case series. Pediatr. Pulmonol. 47, 757\u2013762 (2012).","journal-title":"Pediatr. Pulmonol."},{"key":"993_CR59","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1747-0803.2010.00442.x","volume":"7","author":"VC Thomas","year":"2012","unstructured":"Thomas, V. C. et al. Transcatheter closure of secundum atrial septal defect in infants less than 12 months of age improves symptoms of chronic lung disease. Congenit. Heart Dis. 7, 204\u2013211 (2012).","journal-title":"Congenit. Heart Dis."},{"key":"993_CR60","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1093\/ejcts\/ezu445","volume":"47","author":"AE Baruteau","year":"2015","unstructured":"Baruteau, A. E. et al. Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients. Eur. J. Cardiothorac. Surg. 47, e105\u2013e110 (2015).","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"993_CR61","first-page":"27","volume":"23","author":"M Nagiub","year":"2017","unstructured":"Nagiub, M., Kanaan, U., Simon, D. & Guglani, L. Risk factors for development of pulmonary hypertension in infants with bronchopulmonary dysplasia: systematic review and meta-analysis. Paediatr. Respir. Rev. 23, 27\u201332 (2017).","journal-title":"Paediatr. Respir. Rev."},{"key":"993_CR62","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41372-019-0549-9","volume":"40","author":"S Sheth","year":"2020","unstructured":"Sheth, S., Goto, L., Bhandari, V., Abraham, B. & Mowes, A. Factors associated with development of early and late pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. J. Perinatol. 40, 138\u2013148 (2020).","journal-title":"J. Perinatol."},{"key":"993_CR63","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1159\/000499361","volume":"115","author":"DG Sweet","year":"2019","unstructured":"Sweet, D. G. et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome\u20142019 Update. Neonatology 115, 432\u2013450 (2019).","journal-title":"Neonatology"},{"key":"993_CR64","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000502610","volume":"116","author":"M Vento","year":"2019","unstructured":"Vento, M., Bohlin, K., Herting, E., Roehr, C. C. & Dargaville, P. A. Surfactant administration via thin catheter: a practical guide. Neonatology 116, 211\u2013226 (2019).","journal-title":"Neonatology"},{"key":"993_CR65","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/apa.15011","volume":"109","author":"K Belkhatir","year":"2020","unstructured":"Belkhatir, K. et al. Variations in preterm stabilisation practices and caffeine therapy between two European tertiary level neonatal units. Acta Paediatr. 109, 488\u2013493 (2020).","journal-title":"Acta Paediatr."},{"key":"993_CR66","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1001\/jamapediatrics.2016.3271","volume":"171","author":"S Zivanovic","year":"2017","unstructured":"Zivanovic, S. & Roehr, C. C. One step further toward defining the optimal respiratory care package for neonates: interventions to successfully extubate preterm infants. JAMA Pediatr. 171, 120\u2013121 (2017).","journal-title":"JAMA Pediatr."},{"key":"993_CR67","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4103\/2045-8932.97603","volume":"2","author":"G Hansmann","year":"2012","unstructured":"Hansmann, G. et al. Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension. Pulm. Circ. 2, 170\u2013181 (2012).","journal-title":"Pulm. Circ."},{"key":"993_CR68","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.jpeds.2013.12.011","volume":"164","author":"YS Chang","year":"2014","unstructured":"Chang, Y. S. et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J. Pediatr. 164, 966\u2013972 e966 (2014).","journal-title":"J. Pediatr."},{"key":"993_CR69","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1164\/rccm.201705-0925OC","volume":"197","author":"GR Willis","year":"2018","unstructured":"Willis, G. R. et al. Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. Am. J. Respir. Crit. Care Med. 197, 104\u2013116 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"993_CR70","doi-asserted-by":"publisher","unstructured":"R\u00fcdiger, M., Kirpalani, H., Steinhorn, R., Davis, J. M. & Thebaud, B. How to introduce MSC-based therapy for the developing lung safely into clinical care? Pediatr. Res. https:\/\/doi.org\/10.1038\/s41390-020-0758-0 (2020).","DOI":"10.1038\/s41390-020-0758-0"},{"key":"993_CR71","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/echo.12738","volume":"32","author":"M Nagiub","year":"2015","unstructured":"Nagiub, M., Lee, S. & Guglani, L. Echocardiographic assessment of pulmonary hypertension in infants with bronchopulmonary dysplasia: systematic review of literature and a proposed algorithm for assessment. Echocardiography 32, 819\u2013833 (2015).","journal-title":"Echocardiography"},{"key":"993_CR72","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jpeds.2018.02.006","volume":"197","author":"PT Levy","year":"2018","unstructured":"Levy, P. T., Patel, M. D., Choudhry, S., Hamvas, A. & Singh, G. K. Evidence of echocardiographic markers of pulmonary vascular disease in asymptomatic infants born preterm at one year of age. J. Pediatr. 197, 48\u201356.e2 (2018).","journal-title":"J. Pediatr."},{"key":"993_CR73","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.echo.2019.03.015","volume":"32","author":"MD Patel","year":"2019","unstructured":"Patel, M. D. et al. Echocardiographic assessment of right ventricular afterload in preterm infants: maturational patterns of pulmonary artery acceleration time over the first year of age and implications for pulmonary hypertension. J. Am. Soc. Echocardiogr. 32, 884\u2013894.e4 (2019).","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"993_CR74","doi-asserted-by":"crossref","first-page":"e005336","DOI":"10.1161\/CIRCIMAGING.116.005336","volume":"10","author":"M Koestenberger","year":"2017","unstructured":"Koestenberger, M. et al. Normal reference values and z scores of the pulmonary artery acceleration time in children and its importance for the assessment of pulmonary hypertension. Circ. Cardiovasc. Imaging 10, e005336 (2017).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"993_CR75","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ijcard.2016.03.111","volume":"212","author":"M Koestenberger","year":"2016","unstructured":"Koestenberger, M. et al. Right ventricular outflow tract velocity time integral (RVOT VTI) and tricuspid regurgitation velocity\/RVOT VTI ratio in pediatric pulmonary hypertension. Int. J. Cardiol. 212, 274\u2013276 (2016).","journal-title":"Int. J. Cardiol."},{"key":"993_CR76","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.echo.2013.10.014","volume":"27","author":"PN Jone","year":"2014","unstructured":"Jone, P. N., Hinzman, J., Wagner, B. D., Ivy, D. D. & Younoszai, A. Right ventricular to left ventricular diameter ratio at end-systole in evaluating outcomes in children with pulmonary hypertension. J. Am. Soc. Echocardiogr. 27, 172\u2013178 (2014).","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"993_CR77","doi-asserted-by":"publisher","unstructured":"Koestenberger, M. et al. Right ventricular end-systolic remodeling index in the assessment of pediatric pulmonary arterial hypertension. The European Pediatric Pulmonary Vascular Disease Network (EPPVDN). Pediatr. Res. https:\/\/doi.org\/10.1038\/s41390-020-0748-2 (2020).","DOI":"10.1038\/s41390-020-0748-2"},{"key":"993_CR78","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/s-0035-1556757","volume":"33","author":"AW McCrary","year":"2016","unstructured":"McCrary, A. W. et al. Differences in eccentricity index and systolic-diastolic ratio in extremely low-birth-weight infants with bronchopulmonary dysplasia at risk of pulmonary hypertension. Am. J. Perinatol. 33, 57\u201362 (2016).","journal-title":"Am. J. Perinatol."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41390-020-0993-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41390-020-0993-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41390-020-0993-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:31:46Z","timestamp":1684603906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-020-0993-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["993"],"URL":"https:\/\/doi.org\/10.1038\/s41390-020-0993-4","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]},"assertion":[{"value":"4 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}